The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry

Graeme J Thorn,Emanuela Gadaleta,Maryam Abdollahyan,Dayem Ullah,Rachel Barrow-McGee,J. Louise Jones,Claude Chelala

DOI: https://doi.org/10.1101/2024.05.15.24307435

2024-05-16

Abstract:Breast cancer is the most commonly diagnosed cancer globally and the leading cause of cancer death in women, with ethnic disparities reported in cancer incidence, prognosis, diagnosis and therapeutic response. Although precision oncology holds the promise of revolutionising healthcare, it could exacerbate the racial disparities it seeks to eradicate unless rigorous efforts are made to address research biases. We evaluated the molecular and clinical effects of genetic ancestry in African and South Asian women using a combined cohort of 7,136 breast cancer patients available from four data sources — the 100,000 Genomes Project (UK), The Cancer Genome Atlas (US), the Breast Cancer Now Biobank (London, UK) and Genes & Health (UK). Using patients assigned to the European genetic ancestry as the baseline comparator for all analyses, we find that non-European patients present with breast cancer significantly earlier and die at a younger age. Patients within the African group also have an increased prevalence of higher grade and hormone receptor negative disease. South Asian patients show a small tendency towards lower stage at diagnosis, and a lower tumour mutational burden. We observed significant differences and similarities in the somatic mutational landscape of the non-European populations. Six genes, RBM5, OTOF, FBXW7, NCKAP5, NOTCH3 and GPR158, were differentially mutated across multiple cohorts. Furthermore, potential therapeutic candidates (BRIP1, CDKN2A, CHEK2, FBXW7, GPR158, KDM6A, RET, STK11) were found to be differentially mutated across the African and/or South Asian genetic ancestry groups. Genes with significant differences in germline mutation rates were identified in African and South Asian populations, including those used in current genetic testing (African: TP53, BRCA1, BRCA2, PALB2, p<0.001; South Asian: TP53, BRCA1, BRCA2, p<0.05) as well as those implicated in breast cancer predisposition in the literature, such as CDH1, CDK2A, ERCC3, EPCAM, FANCA, FANCC, POLE and PMS2. There is a higher propensity for BRCAness in the African population, with a lower rate in the South Asian population, serving as a potential prognostic indicator into the response to therapies such as PARP inhibitors. Our study confirms the under-representation of non-European ethnic minority groups within research studies, clinical applications and biobanks, with none of the resources able to recapitulate the ethnic diversity of their representative geographical locations (UK, London and US). Finally, our findings advocate for the implementation of ancestry-specific germline mutation breast cancer screening windows and germline screening panels. This study harnesses multimodal data to improve our understanding of ancestry-associated differences in breast cancer and highlight opportunities to advance health equity in breast cancer thus taking one step closer to achieving the promise of equitable precision oncology.